Rongchang Biology: Taetasipu achieves the main research endpoint in the Phase III clinical study of primary Sjogren's syndrome.

Rongchang Bio announced on the evening of August 13th that the company's independently developed BLyS/APRIL dual-target fusion protein innovative drug, taixisip, used in the Phase III clinical study for the treatment of primary Sjogren's syndrome, has achieved the main research endpoints as designed in the clinical trial protocol. Clinical study results show that taixisip can effectively and sustainably improve the clinical symptoms of patients with Sjogren's syndrome, demonstrating good efficacy and safety. The company will promptly submit a marketing application to the National Medical Products Administration Drug Evaluation Center.